Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding
Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can be considered as universal hemostatic agents. RMP are produced from red blood cells using a high-pressure extrusion membrane shear process and can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired.
1. A process for producing red cell membrane derived microparticles (RMP) having hemostatic activity without thrombogenic activity comprising the steps of:
suspending red blood cells in an aqueous diluent to form a cell suspension;
pressurizing the cell suspension;
extruding the pressurized cell suspension into a region of lower pressure to generate shear forces on the suspended red blood cells whereby the suspended cells are converted into a crude RMP suspension; and
removing any whole red blood cells from the crude RMP suspension to make a final RMP suspension having hemostatic activity without thrombogenic activity.
2. The process according to claim 1 , wherein a French Press is used to pressurize and extrude the cell suspension.
3. The process according to claim 1 , wherein whole red blood cells are removed from the crude RMP suspension by centrifugation.
4. The process according to claim 3 , wherein RMP are removed from the crude RMP suspension by centrifugation.
5. The process according to claim 1 , wherein whole red blood cells are removed from the crude RMP suspension by filtration.
6. The process according to claim 1 further comprising a step of washing the red blood cells with saline prior to the step of suspending.
7. The process according to claim 6 , wherein the saline further comprises EDTA.
8. The process according to claim 1 further comprising a step of lyophilizing the final RMP suspension.
9. The process according to claim 1 wherein the red blood cells are from an autologous donor.
10. The process according to claim 1 , wherein the red blood cells are selected from the group consisting of type A—Rh positive, type A—Rh negative, type B—Rh positive, type B—Rh negative, type AB—Rh positive, type AB—Rh negative, type O—Rh positive and type O, Rh negative.
11. The process according to claim 10 , wherein the red blood cells are type O—Rh negative.